Philips Q3 2026: A 24% EPS Beat and the Respironics Overhang Explained

As seen on the 24/7 Wall St. homepage on November 3, 2026.

PHG Philips
Q3 2026
EPS
$0.45
est $0.36 +24.3%
Revenue
$4.91B
est $4.42B +11.2%

Buyers are treating the Respironics DOJ settlement provision as the last big overhang, even though it cut GAAP net income to $31.3 million from $209.2 million a year ago. Adjusted results came in above expectations on both lines, and management reiterated full-year comparable sales guidance.

Continue ReadingShow less

Philips posted adjusted diluted EPS of $0.45 for the third quarter of 2026, beating expectations. Revenue and the adjusted EBITA margin also came in ahead, with the margin expanding to 13.0%.

A $322 million DOJ settlement provision tied to the Respironics recall was the single largest drag on reported results, pushing GAAP net income down to $31.3 million. Investors appear to be treating the agreement in principle with the Department of Justice as the removal of the most significant remaining legal overhang.

Demand across the healthcare technology portfolio was broad-based, with comparable order intake up 8% and led by Diagnosis and Treatment. CEO Roy Jakobs credited AI-enabled innovations, including the new CT platforms Verida and Rembra, the Alturion ultrasound system, and the HealthSuite Imaging cloud solution, for driving customer interest.

Sponsored

Productivity initiatives delivered net savings of roughly $427 million year-to-date, supporting gross margin expansion and offsetting cost pressures. Free cash flow reached $430 million.

Management reiterated full-year 2026 guidance for an adjusted EBITA margin of 13.5% to 14.0%, assuming the DOJ settlement is paid in the first quarter of 2027. Ongoing proceedings, including a US State Attorneys General investigation related to Respironics, sit outside those guidance assumptions and remain a risk for investors.

Mentioned: PHG, RYLPF